J. Tillner

1.9k citations

29 papers · 880 indexed · h-index 14

Impact in

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes Treatment and Management
- Diabetes Management and Research
Oncology top 10%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research

Papers in ⓘ

Endocrinology, Diabetes and Metabolism 10
- Diabetes Treatment and Management 9
Oncology 15
- HER2/EGFR in Cancer Research 9
- Colorectal Cancer Treatments and Studies 7
- Cancer Treatment and Pharmacology 4

Co-authors: Federico Rojo (7 shared papers)Dirk Weber (8 shared papers)Lenore Teichert (3 shared papers)Tanja Trarbach (4 shared papers)N. Schleucher (4 shared papers)U. Vanhoefer (4 shared papers)José Baselga (2 shared papers)Mitra Tewes (1 shared paper)
Journals: Journal of Clinical Oncology (13 papers)Diabetes Obesity and Metabolism (2 papers)Journal of Nuclear Medicine (2 papers)Obesity (2 papers)Scientific Reports (1 paper)
Partner nations: Germany United States Sweden

In The Last Decade

J. Tillner

29 papers receiving 857 citations

Peers

Countries citing papers authored by J. Tillner

Since Specialization

Citations

This map shows the geographic impact of J. Tillner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Tillner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Tillner more than expected).

Fields of papers citing papers by J. Tillner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Tillner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Tillner. The network helps show where J. Tillner may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Tillner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Tillner Line = papers co-authored together J. Tillner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor Journal of Clinical Oncology ·U. Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, N. Schleucher, Oliver Rosen, J. Tillner, Andreas Kovar, Ada Braun, Tanja Trarbach, S. Seeber, A. Harstrick, José Baselga	2003	221
2	A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials Diabetes Obesity and Metabolism ·J. Tillner, Maximilian Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart, Philip J. Larsen	2018	135
3	Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer British Journal of Cancer ·Ullrich Graeven, B. Kremer, Th Südhoff, B. Killing, Federico Rojo, Dirk Weber, J. Tillner, Çağlar Ünal, Wolff Schmiegel	2006	83
4	A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·Christian Kollmannsberger, Marcus M. Schittenhelm, Friedemann Honecker, J. Tillner, Dirk Weber, Karin Oechsle, Lothar Kanz, Carsten Bokemeyer	2006	79
5	Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes Diabetes Obesity and Metabolism ·Masanari Shiramoto, Takashi Eto, S. Irie, A. Fukuzaki, Lenore Teichert, J. Tillner, Yoshinori Takahashi, Masayoshi Koyama, Raphael Dahmen, Tim Heise, R. H. A. Becker	2014	76
6	Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes Scientific Reports ·Olof Eriksson, Torsten Haack, Youssef Hijazi, Lenore Teichert, Veronique Tavernier, Iina Laitinen, Jan Erik Berglund, Gunnar Antoni, Irina Velikyan, L. E. B. Johansson, Stefan Pierrou, Michael Wagner, J. Tillner	2020	34
7	Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) Journal of Clinical Oncology ·R. Salazar, Josep Tabernero, Federico Rojo, E. Jiménez, I. Montaner, E. Casado, Gianluca Sala, J. Tillner, Rajesh Malik, José Baselga	2004	33
8	Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial Obesity ·Katie L. Whytock, Elvis Á. Carnero, Rick B. Vega, J. Tillner, C. Bock, Karthik Chivukula, Fanchao Yi, Christian Meyer, Steven R. Smith, Lauren M. Sparks	2021	25
9	Glucagon‐like peptide‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial Obesity ·Karen D. Corbin, Elvis Á. Carnero, Timothy D. Allerton, J. Tillner, C. Bock, Pierre‐Philippe Luyet, Britta Göbel, Kevin D. Hall, Stephanie A. Parsons, Éric Ravussin, Steven R. Smith	2023	22
10	Amino-Alkyl-Cyclohexanes as a Novel Class of Uncompetitive NMDA Receptor Antagonists Current Pharmaceutical Design ·Wojciech Danysz, Chris G. Parsons, Aigars Jirgensons, Valerjans Kauss, J. Tillner	2002	19
11	A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity Journal of the Endocrine Society ·Rick B. Vega, Katie L. Whytock, Johann Gassenhuber, Britta Goebel, J. Tillner, Inoncent Agueusop, Agnieszka D. Truax, Gongxin Yu, Elvis Á. Carnero, Nidhi Kapoor, Stephen J. Gardell, Lauren M. Sparks, Steven R. Smith	2021	16
12	EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study Psychopharmacology ·David C. Mamo, Ewen Sedman, J. Tillner, Edward M. Sellers, Myroslava K. Romach, Shitij Kapur	2004	14
13	Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) Journal of Clinical Oncology ·R. Salazar, Josep Tabernero, Federico Rojo, E. Jiménez, I. Montaner, E. Casado, Gianluca Sala, J. Tillner, Rajesh Malik, José Baselga	2004	14
14	Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma Journal of Clinical Oncology ·Stephen M. Rao, Naureen Starling, Mgbeosuru Benson, Alison Massey, A. Wotherspoon, Gina Brown, N. Anstice, J. Tillner, Dirk Weber, David Cunningham	2005	14
15	A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers Journal of Clinical Oncology ·Tanja Trarbach, Thomas Beyer, N. Schleucher, J. Stattaus, Stefan Müeller, D. Appel, J. Tillner, K. W. Schmid, S. Seeber, U. Vanhoefer	2004	11
16	A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies Journal of Clinical Oncology ·Takahiro Doi, Atsushi Ohtsu, N. Saijo, Hiroya Takiuchi, Y. Ohhashi, Dirk Weber, J. Tillner, Takao Sakata, Haibin Sun, Federico Rojo	2005	9
17	Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects Clinical Pharmacology in Drug Development ·J. Tillner, Anne Lehmann, Tobias Paehler, Zoltán Lukács, Sven Ruf, Thorsten Sadowski, Jean‐Louis Pinquier, Hartmut Ruetten	2015	8
18	Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes Journal of Nuclear Medicine ·Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Iina Laitinen, Philip J. Larsen, Jan Erik Berglund, Gunnar Antoni, L. E. B. Johansson, Stefan Pierrou, J. Tillner, Michael Wagner	2020	8
19	A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies Journal of Clinical Oncology ·Michael V. Seiden, H. A. Burris, U. Matulonis, James B. Hall, D. Armstrong, J Speyer, J. Tillner, Dirk Weber, Franco M. Muggia	2005	8
20	Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma Journal of Clinical Oncology ·Tanja Trarbach, N. Schleucher, Dirk Weber, J. Tillner, I. Fassmann, S. Seeber, U. Vanhoefer	2005	8

About J. Tillner

J. Tillner is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology, Endocrine and Autonomic Systems, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 29 papers that have together received 880 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Diabetes Treatment and Management (9 papers), Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Pancreatic function and diabetes (4 papers), Cancer Treatment and Pharmacology (4 papers), Metabolism, Diabetes, and Cancer (3 papers) and Receptor Mechanisms and Signaling (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (268 citations), Oncology (423 citations), Pulmonary and Respiratory Medicine (272 citations), Pharmacology (94 citations) and Radiology, Nuclear Medicine and Imaging (103 citations). J. Tillner has collaborated with scholars based in Germany, United States and Sweden. Frequent co-authors include Federico Rojo, Dirk Weber, Lenore Teichert, Tanja Trarbach, N. Schleucher, U. Vanhoefer, José Baselga, Mitra Tewes, S. Seeber and Ada Braun. Their work appears in journals such as Journal of Clinical Oncology, Diabetes Obesity and Metabolism, Journal of Nuclear Medicine, Obesity and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact